Skip to content

Schizophrenia Study for Participants on Clozapine

Schizophrenia

This study will look at how safe and how well the investigational drug NaBen®, in addition to clozapine, works in improving the symptoms of refractory schizophrenia.
Schizophrenia is a mental disorder consisting of positive symptoms, negative symptoms, and an inability to pay attention or process information clearly. Sodium benzoate has been shown to regulate brain chemicals that may help to improve some of the schizophrenia symptoms.
The active ingredient in the NaBen® tablet is sodium benzoate. Sodium benzoate is naturally found in cranberries, prunes, plums, cinnamon, ripe cloves, and apples.

null

Conditions de participation

  • Sexe:

    Male, Female

  • Âges admissibles:

    18 to 55

Critères de participation

Inclusion Criteria:
Male or female between 18-55 years of age.
Diagnosis of schizophrenia
Receiving clozapine
Has an identified caregiver or support person to assist with completing study rating scales.
Exclusion Criteria:
Serious medical illnesses, epilepsy, head trauma, neurological illness, movement disorders.
Current substance abuse or history in the past 6 months
Certain medications as determined by the research team.

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: REB17-1845